Methadone maintenance treatment and mortality in HIV-positive people who inject opioids in China;El tratamiento de mantenimiento con metadona en seropositivos que se inyectan opiáceos en China

Bulletin of the World Health Organization

Volumn 91, Issue 2, 2013, Pages 93-101

  Zhao, Yan ^a   Shi, Cynthia X ^a   McGoogan, Jennifer M ^a   Rou, Keming ^a   Zhang, Fujie ^a   Wu, Zunyou ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; METHADONE; OPIATE DERIVATIVE;

COHORT ANALYSIS; DEMOGRAPHY; DISEASE TREATMENT; HEMOGLOBIN; HUMAN IMMUNODEFICIENCY VIRUS; INFECTIOUS DISEASE; MORTALITY; MULTIVARIATE ANALYSIS;

ADOLESCENT; ADULT; AGE; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CHINA; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; EDUCATIONAL STATUS; ETHNICITY; FEMALE; FOLLOW UP; GENDER; GENERAL HOSPITAL; HEALTH CARE FACILITY; HEALTH CENTER; HEMOGLOBIN BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTIOUS DISEASE HOSPITAL; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MORTALITY;

CHINA;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84873282496     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.12.108944     Document Type: Article

References (44)

1. 2012 China AIDS response progress report. Beijing: Ministry of Health; 2012.
2. Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008;372:1733-45. doi:10.1016/S0140-6736(08)61311-2
3. Wu Z, Rou K, Cui H. The HIV/AIDS epidemic in China: history, current strategies and future challenges. AIDS Educ Prev 2004;16(Suppl A):7-17. doi:10.1521/aeap.16.3.5.7.35521
4. National Narcotics Control Commission. Annual report on drug control in China 2011. Beijing: Ministry of Public Security; 2011.
5. Wu Z, Sullivan SG, Wang Y, Rotheram-Borus MJ, Detels R. Evolution of China's response to HIV/AIDS. Lancet 2007;369:679-90. doi:10.1016/S0140-6736(07)60315-8
6. Yin W, Hao Y, Sun X, Gong X, Li F, Li J et al. Scaling up the national methadone maintenance treatment program in China: achievements and challenges. Int J Epidemiol 2010;39(Suppl 2):ii29-37. doi:10.1093/ije/dyq210
7. Han M, Chen Q, Hao Y, Hu Y, Wang D, Gao Y et al. Design and implementation of a China comprehensive AIDS response programme (China CARES), 2003-08. Int J Epidemiol 2010;39(Suppl 2):ii47-55. doi:10.1093/ije/dyq212
8. National Center for AIDS/STD Control and Prevention, China CDC. National monthly report on statistics of epidemics and prevention and treatment of HIV/AIDS, STD and hepatitis C in China (April 2012). Beijing: National Center for AIDS/STD Control and Prevention, China CDC; 2012.
9. Zhang F, Dou Z, Yu L, Xu J, Jiao JH, Wang N et al. The effect of highly active antiretroviral therapy on mortality among HIV-infected former plasma donors in China. Clin Infect Dis 2008;47:825-33. doi:10.1086/590945
10. Zhang F, Dou Z, Ma Y, Zhao Y, Liu Z, Bulterys M et al. Five-year outcomes of the China National Free Antiretroviral Treatment Program. Ann Intern Med 2009;151:241-51, W-52.
11. Ma Y, Zhao D, Yu L, Bulterys M, Robinson ML, Zhao Y et al. Predictors of virologic failure in HIV-1-infected adults receiving first-line antiretroviral therapy in 8 provinces in China. Clin Infect Dis 2010;50:264-71. doi:10.1086/649215
12. Zhang F, Dou Z, Ma Y, Zhang Y, Zhao Y, Zhao D et al. Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study. Lancet Infect Dis 2011;11:516-24. doi:10.1016/S1473-3099(11)70097-4
13. Metzger DS, Zhang Y. Drug treatment as HIV prevention: expanding treatment options. Curr HIV/AIDS Rep 2010;7:220-5. doi:10.1007/s11904-010-0059-z
14. Wolfe D, Carrieri MP, Shepard D. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet 2010;376:355-66. doi:10.1016/S0140-6736(10)60832-X
15. Dou Z, Chen RY, Xu J, Ma Y, Jiao JH, Durako S et al. Changing baseline characteristics among patients in the China National Free Antiretroviral Treatment Program, 2002-09. Int J Epidemiol 2010;39(Suppl 2):ii56-64. doi:10.1093/ije/dyq215
16. Malta M, Bastos FI, da Silva CMFP, Pereira GFM, Lucena FFA, Fonseca MGP et al. Differential survival benefit of universal HAART access in Brazil: a nation-wide comparison of injecting drug users versus men who have sex with men. J Acquir Immune Defic Syndr 2009;52:629-35. doi:10.1097/QAI.0b013e3181b31b8a
17. Larsen MV, Omland LH, Gerstoft J, Larsen CS, Jensen J, Obel N et al. Impact of injecting drug use on mortality in Danish HIV-infected patients: a nation-wide population-based cohort study. Addiction 2010;105:529-35. doi:10.1111/j.1360-0443.2009.02827.x
18. Grigoryan A, Hall HI, Durant T, Wei X. Late HIV diagnosis and determinants of progression to AIDS or death after HIV diagnosis among injection drug users, 33 US states, 1996-2004. PLoS One 2009;4:e4445. doi:10.1371/journal.pone.0004445
19. Lert F, Kazatchkine MD. Antiretroviral HIV treatment and care for injecting drug users: an evidence-based overview. Int J Drug Policy 2007;18:255-61. doi:10.1016/j.drugpo.2007.05.002
20. Roux P, Carrieri MP, Villes V, Dellamonica P, Poizot-Martin I, Ravaux I et al. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study. Addiction 2008;103:1828-36. doi:10.1111/j.1360-0443.2008.02323.x
21. Roux P, Carrieri MP, Cohen J, Ravaux I, Poizot-Martin I, Dellamonica P et al. Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment. Clin Infect Dis 2009;49:1433-40. doi:10.1086/630209
22. Weber R, Huber M, Rickenbach M, Furrer H, Elzi L, Hirschel B et al. Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study. HIV Med 2009;10:407-16. doi:10.1111/j.1468-1293.2009.00701.x
23. Uhlmann S, Milloy MJ, Kerr T, Zhang R, Guillemi S, Marsh D et al. Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction 2010;105:907-13. doi:10.1111/j.1360-0443.2010.02905.x
24. Pang L, Hao Y, Mi G, Wang C, Luo W, Rou K et al. Effectiveness of first eight methadone maintenance treatment clinics in China. AIDS 2007;21(Suppl 8):S103-7. doi:10.1097/01.aids.0000304704.71917.64
25. Li L, Lin C, Wan D, Zhang L, Lai W. Concurrent heroin use among methadone maintenance clients in China. Addict Behav 2012;37:264-8. doi:10.1016/j.addbeh.2011.11.004
26. Sullivan LE, Metzger DS, Fudala PJ, Fiellin DA. Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users. Addiction 2005;100:150-8. doi:10.1111/j.1360-0443.2004.00963.x
27. Achmad YM, Istiqomah AN, Iskandar S, Wisaksana R, van Crevel R, Hidayat T. Integration of methadone maintenance treatment and HIV care for injecting drug users: a cohort study in Bandung, Indonesia. Acta Med Indones 2009;41(Suppl 1):23-7. doi:10.1093/ije/dyq213
28. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 revision. Geneva: World Health Organization; 2010.
29. Ministry of Health Working Group on Clinical AIDS Treatment. China free antiretroviral treatment manual. Beijing: People's Medical Publishing House; 2012.
30. Community maintenance treatment procedures for opiate addicts. Beijing; Ministry of Health, Ministry of Public Security, State Food and Drug Administration; 2006. [Chinese].
31. Mao Y, Wu Z, Poundstone K, Wang C, Qin Q, Ma Y et al. Development of a unified web-based national HIV/AIDS information system in China. Int J Epidemiol 2010;39(Suppl 2):ii79-89. doi:10.1093/ije/dyq213
32. Ma Y, Zhang F, Zhao Y, Zang C, Zhao D, Dou Z et al. Cohort profile: the Chinese national free antiretroviral treatment cohort. Int J Epidemiol 2010;39:973-9. doi:10.1093/ije/dyp233
33. Spire B, Lucas GM, Carrieri MP. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). Int J Drug Policy 2007;18:262-70. doi:10.1016/j.drugpo.2006.12.014
34. Wood E, Kerr T, Zhang R, Guillemi S, Palepu A, Hogg RS et al. Poor adherence to HIV monitoring and treatment guidelines for HIV-infected injection drug users. HIV Med 2008;9:503-7. doi:10.1111/j.1468-1293.2008.00582.x
35. Lawrinson P, Ali R, Buavirat A, Chiamwongpaet S, Dvoryak S, Habrat B et al. Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS. Addiction 2008;103:1484-92. doi:10.1111/j.1360-0443.2008.02249.x
36. Berg KM, Mouriz J, Li X, Duggan E, Goldberg U, Arnsten JH. Rationale, design, and sample characteristics of a randomized controlled trial of directly observed antiretroviral therapy delivered in methadone clinics. Contemp Clin Trials 2009;30:481-9. doi:10.1016/j.cct.2009.05.003
37. Lucas GM, Mullen BA, Weidle PJ, Hader S, McCaul ME, Moore RD. Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. Clin Infect Dis 2006;42:1628-35. doi:10.1086/503905
38. Gupta A, Nadkarni G, Yang W-T, Chandrasekhar A, Gupte N, Bisson GP et al. Early mortality in adults initiating antiretroviral therapy (ART) in low-and middle-income countries (LMIC): a systematic review and meta-analysis. PLoS One 2011;6:e28691. doi:10.1371/journal.pone.0028691
39. Volberding PA, Levine AM, Dieterich D, Mildvan D, Mitsuyasu R, Saag M; Anemia in HIV Working Group. Anemia in HIV infection: clinical impact and evidence-based management strategies. Clin Infect Dis 2004;38:1454-63. doi:10.1086/383031
40. O'Brien ME, Kupka R, Msamanga GI, Saathoff E, Hunter DJ, Fawzi WW. Anemia is an independent predictor of mortality and immunologic progression of disease among women with HIV in Tanzania. J Acquir Immune Defic Syndr 2005;40:219-25. doi:10.1097/01.qai.0000166374.16222.a2
41. Fregonese F, Collins IJ, Jourdain G, Lecoeur S, Cressey TR, Ngo-Giang-Houng N et al. Predictors of 5-year mortality in HIV-infected adults starting highly active antiretroviral therapy in Thailand. J Acquir Immune Defic Syndr 2012;60:91-8. doi:10.1097/QAI.0b013e31824bd33f
42. Celentano DD, Vlahov D, Cohn S, Shadle VM, Obasanjo O, Moore RD. Self-reported antiretroviral therapy in injection drug users. JAMA 1998;280:544-6. doi:10.1001/jama.280.6.544
43. Alistar SS, Owens DK, Brandeau ML. Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine. PLoS Med 2011;8:e1000423. doi:10.1371/journal.pmed.1000423
44. Tran BX, Ohinmaa A, Duong AT, Do NT, Nguyen LT, Mills S et al. Cost-effectiveness of methadone maintenance treatment for HIV-positive drug users in Vietnam. AIDS Care 2012;24:283-90. doi:10.1080/09540121.2011.608420